Literature DB >> 9365154

Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease with special attention for IgA-class antibodies.

P Gigase1, L S De Clerck, K A Van Cotthem, C H Bridts, W J Stevens, M Van Outryve, P A Pelckmans.   

Abstract

Perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) of the IgG class have been reported in inflammatory bowel disease, mainly in ulcerative colitis. Since this disease affects the gastrointestinal tract, we determined whether IgA class ANCA were present in inflammatory bowel disease. We used an indirect immunofluorescence assay for IgG and IgA ANCA testing. Sera from 34 patients with Crohn's disease and 29 patients with ulcerative colitis were collected together with clinical and laboratory data. We found IgA class ANCA of a perinuclear type in 52% of patients with ulcerative colitis and in 9% of Crohn's disease patients. There was a significant association between the presence of IgA ANCA and the occurrence of blood in the feces in the ulcerative colitis group (P = 0.03). IgG ANCA was found in 56% of patients with ulcerative colitis and in 7% of patients with Crohn's disease. Because of partial overlap between IgG and IgA ANCA positivity, the sensitivity of ANCA testing in ulcerative colitis increased from 56% up to 78% by combining IgG and IgA assays. In conclusion, IgA ANCA occurs with a high prevalence in ulcerative colitis. Moreover there is a possible relationship between IgA ANCA and disease activity in ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365154     DOI: 10.1023/a:1018803509150

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.

Authors:  A Saxon; F Shanahan; C Landers; T Ganz; S Targan
Journal:  J Allergy Clin Immunol       Date:  1990-08       Impact factor: 10.793

2.  Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients.

Authors:  S R Targan; C J Landers; L Cobb; R P MacDermott; A Vidrich
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

3.  IgA immune complexes in Henoch-Schönlein purpura.

Authors:  R J Levinsky; T M Barratt
Journal:  Lancet       Date:  1979-11-24       Impact factor: 79.321

4.  IgA antibodies directed against cytoplasmic antigens of polymorphonuclear leukocytes in patients with Henoch-Schoenlein purpura.

Authors:  A W vd Wall Bake; S Lobatto; L Jonges; M R Daha; L A van Es
Journal:  Adv Exp Med Biol       Date:  1987       Impact factor: 2.622

5.  Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates.

Authors:  A H Mulder; J Broekroelofs; G Horst; P C Limburg; G F Nelis; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

6.  Neutrophil autoantibodies in inflammatory bowel disease: are they important?

Authors:  F Shanahan
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

7.  Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  G Cambridge; D S Rampton; T R Stevens; D A McCarthy; M Kamm; B Leaker
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

8.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders.

Authors:  M P Stoffel; E Csernok; C Herzberg; T Johnson; S F Carroll; W L Gross
Journal:  Clin Exp Immunol       Date:  1996-04       Impact factor: 4.330

10.  Neutrophil activation in vitro and in vivo in Wegener's granulomatosis.

Authors:  E Brouwer; M G Huitema; A H Mulder; P Heeringa; H van Goor; J W Tervaert; J J Weening; C G Kallenberg
Journal:  Kidney Int       Date:  1994-04       Impact factor: 10.612

View more
  4 in total

1.  IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis.

Authors:  James M Kelley; Paul A Monach; Chuanyi Ji; Yebin Zhou; Jianming Wu; Sumiaki Tanaka; Alfred D Mahr; Sharleen Johnson; Carol McAlear; David Cuthbertson; Simon Carette; John C Davis; Paul F Dellaripa; Gary S Hoffman; Nader Khalidi; Carol A Langford; Phillip Seo; E William St Clair; Ulrich Specks; John H Stone; Robert F Spiera; Steven R Ytterberg; Peter A Merkel; Jeffrey C Edberg; Robert P Kimberly
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-06       Impact factor: 11.205

2.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

3.  IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Authors:  Esha Oommen; Amber Hummel; Lisa Allmannsberger; David Cuthbertson; Simon Carette; Christian Pagnoux; Gary S Hoffman; Dieter E Jenne; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry Moreland; Philip Seo; Antoine Sreih; Steven R Ytterberg; Peter A Merkel; Ulrich Specks; Paul A Monach
Journal:  Clin Exp Rheumatol       Date:  2017-03-01       Impact factor: 4.473

Review 4.  Wegener's granulomatosis: a model of auto-antibodies in mucosal autoimmunity.

Authors:  James M Kelley; Jeffrey C Edberg; Robert P Kimberly
Journal:  Clin Immunol       Date:  2009-05-23       Impact factor: 3.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.